65003-28-3

Usage

Uses

Used in Pharmaceutical Industry:
Methanone, (3,4-dinitrophenyl)-4-Morpholinylis used as a reagent in organic synthesis for the development of new pharmaceutical compounds. Its unique structure and properties enable it to undergo various chemical reactions and form stable intermediates, making it a valuable component in the creation of new drugs.
Used in Agrochemical Industry:
Methanone, (3,4-dinitrophenyl)-4-Morpholinylis used as a tool in chemical research for the development of new agrochemicals. Its ability to form stable intermediates and undergo various chemical reactions makes it useful in the creation of new pesticides and other agrochemical products.
Used in Materials Science:
Methanone, (3,4-dinitrophenyl)-4-Morpholinylis used as a component in the development of new materials. Its unique structure and properties make it valuable in the creation of advanced materials with specific properties for various applications.
Used in Medicinal Chemistry and Drug Discovery:
Methanone, (3,4-dinitrophenyl)-4-Morpholinylis used as a research tool in medicinal chemistry and drug discovery. Its potential uses in this field make it an important chemical for the development of new therapeutic agents and treatments.

Upstream product

• 110-91-8 morpholine 
• 24376-18-9 3,4-dinitrobenzoyl chloride 
• 528-45-0 3,4-dinitrobenzoic acid 

Downstream Products

• 825619-03-2 4-(3,4-dinitrobenzyl)-morpholine 
• 65003-29-4 (3,4-diaminophenyl)(morpholin-4-yl)methanone 
• 825619-02-1 4-morpholin-4-ylmethylbenzene-1,2-diamine 
• 825619-29-2 4-((2-(4-nitro-1H-pyrazol-3-yl)-1H-benzo[d]imidazole-5-yl)methyl)morpholine 
• 1254229-30-5 N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide 

Relevant academic research and scientific papers

Pyrazole spleen tyrosine kinase inhibitor as well as preparation method and application thereof

The invention discloses a pyrazole spleen tyrosine kinase inhibitor, a preparation method thereof, a pharmaceutical composition containing the same, and application of the pyrazole spleen tyrosine kinase inhibitor and the pharmaceutical composition in the preparation of drugs for treating Syk-mediated diseases including cancers, inflammatory diseases and the like.

Pyrazole derivatives and use thereof

The invention relates to a substituted pyrazole derivative for inhibiting over-expression of protein kinase, and a stereoisomer, a geometrical isomer, a tautomer, an oxynitride, a solvate, a hydrate, a metabolite, an ester, a pharmaceutically acceptable s

As Aurora kinase inhibitor derivatives

The present invention relates to a substituted pyrazole derivative used for inhibiting Aurora kinase and represented by formula (I) or formula (Ia), or stereo isomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, a medicinal composition containing the above compounds as active ingredients, and a use of the compounds and the medicinal composition in preparation of medicines for protecting, processing, treating or mitigating proliferative diseases of patients.

Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors

In this work, we describe the use of the rule of 3 fragment-based strategies from biochemical screening data of 1100 in-house, small, low molecular weight fragments. The sequential combination of in silico fragment hopping and fragment linking based on S1

HPK1 INHIBITORS AND METHODS OF USING SAME

Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).

PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES

A compound represented by the general Formula (I), whereinhydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; R1 represents -X-Q-P, wherein X is absent or represents –CH2-, –C(O)-, or –C(O)NH-(CH2)k-, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight-or branched-chain C1-C3 alkyl, –(CH2)l-NR2R3, or–(CH2)m-C(O)-NR2R3, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent;and R2and R3 independently represent C1 or C2 alkyl, or R2 and R3 together with nitrogen atom to which they are both attached form a 6- membered saturated heterocyclicring, wherein one of carbon atoms can be replaced with oxygen, -NH-or –N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases. (I)

Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors

Novel pyrazole-benzimidazole derivatives have been designed and synthesized. The entire target compounds were determined against cancer cell lines U937, K562, A549, LoVo and HT29 and were screened for Aurora A/B kinase inhibitory activity in vitro. The compounds 7a, 7b, 7i, 7k and 7l demonstrated significant cancer cell lines and Aurora A/B kinase inhibitory activities. Molecular modeling studies suggested the derivatives have bound in the active site of Aurora A kinase through the formation of four hydrogen bonds. Quantum chemical studies were carried out on these compounds to understand the structural features essential for activity. The cellular activity of 7k was also tested by immunofluorescence.

PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA

The invention provides combinations of an ancillary compound and a compound which is a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. Also p

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive tar

PHARMACEUTICAL COMBINATIONS

The invention provides combinations of an ancillary compound of the formula (0): and a compound of the formula (I'): Also provided are crystalline forms of the constituent compounds, methods for making them and their uses in treating cancers.